Type 2 DiabetesPhase 2NCT00628212

Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes

A Phase 2 study testing Teneligliptin 10mg, Teneligliptin 20 mg and Teneligliptin 40 mg in people with Type 2 Diabetes, run by Tanabe Pharma Corporation at 1 site in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration once daily in multi-center, randomized… Read more about this study

Who is it for?: Ages 20 to 75 years
Conditions the study is for: Type 2 Diabetes
What is being tested?: Teneligliptin 10mg, Teneligliptin 20 mg and Teneligliptin 40 mg
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 324 participants
Where: 1 siteJapan
Study dates: Jan 2008to Jan 2009
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 20 to 75 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Patients who are 20 - 75 years old
Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug
Patients whose HbA1c is 6.5 - 9.5%
Patients who were not administered drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.

Who cannot join

Patients with type 1 diabetes, diabetes mellitus caused by pancreas failure, or secondary diabetes (Cushing disease, acromegaly, etc)
Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification
Patients with serious diabetic complications
Patients who are habitual excessive alcohol consumption.
Patients with severe hepatic disorder or severe renal disorder.
Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

Trial locations and contacts

1 site in 1 country.

Japan1 site

Study site
Takikawa-shi, Hokkaido

Other trials in Japan

About this study

Official title: A Phase II, Double-Blind, Placebo-Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus -Confirmative Study-

Conditions: Type 2 Diabetes
Being tested: Teneligliptin 10mg, Teneligliptin 20 mg, Teneligliptin 40 mg, Placebo
Keywords: insulin resistance
Medical subject headings: Diabetes Mellitus, Type 2, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Teneligliptin 10mgDrug
Also called MP-513
Teneligliptin 20 mgDrug
Also called MP-513
Teneligliptin 40 mgDrug
Also called MP-513
PlaceboDrug

Study groups in NCT00628212
Study group	Role	What they receive
Teneligliptin 10 mg	Experimental	Teneligliptin 10 mg, orally, once daily Receives: Drug: Teneligliptin 10mg
Teneligliptin 20 mg	Experimental	Teneligliptin 20 mg, orally, once daily Receives: Drug: Teneligliptin 20 mg
Teneligliptin 40 mg	Experimental	Teneligliptin 40 mg, orally, once daily Receives: Drug: Teneligliptin 40 mg
Placebo	Placebo comparator	Teneligliptin placebo-matching tablets, orally, once daily Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline in HbA1c at Week 12
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.
Measured: 12 weeks

Secondary outcomes (3)

Change From Baseline in Fasting Plasma Glucose at Week 12
The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate.
Measured: 12 weeks
Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12
The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate.
Measured: 12 weeks
Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12
The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate.
Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Jan 2008Jan 2009

First posted4 Mar 2008 (estimated)
Study startJan 2008
Primary completionDec 2008
Study completionJan 2009

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 324 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00628212
Sponsor's protocol ID: 3000-A4
Status last verified: Dec 2025
First submitted: 24 Feb 2008
Last updated: 2 Jan 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

All Type 2 Diabetes trials

Study at a glance

From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase II, Double-Blind, Placebo-Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus -Confirmative Study-
ClinicalTrials.gov ID: NCT00628212
Acronym / sponsor ID: 3000-A4
Conditions: Type 2 Diabetes
Keywords: insulin resistance
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 324 participants (actual)
Lead sponsor: Tanabe Pharma CorporationIndustry (pharma, biotech, devices)
Study start: Jan 2008
Primary completion: Dec 2008 (actual)
Study completion: Jan 2009 (actual)
First posted: 4 Mar 2008 (estimated)
Results: Posted 31 May 2013

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 4

Arm	Type	Receives
Teneligliptin 10 mg	Experimental	Drug: Teneligliptin 10mgTeneligliptin 10 mg, orally, once daily
Teneligliptin 20 mg	Experimental	Drug: Teneligliptin 20 mgTeneligliptin 20 mg, orally, once daily
Teneligliptin 40 mg	Experimental	Drug: Teneligliptin 40 mgTeneligliptin 40 mg, orally, once daily
Placebo	Placebo comparator	Drug: PlaceboTeneligliptin placebo-matching tablets, orally, once daily

Who may qualify

Ages: 20 to 75 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Patients who are 20 - 75 years old
Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug
Patients whose HbA1c is 6.5 - 9.5%
Patients who were not administered drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.

Key exclusion criteria (6 listed)

Patients with type 1 diabetes, diabetes mellitus caused by pancreas failure, or secondary diabetes (Cushing disease, acromegaly, etc)
Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification
Patients with serious diabetic complications
Patients who are habitual excessive alcohol consumption.
Patients with severe hepatic disorder or severe renal disorder.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Teneligliptin 10mgAlso: MP-513	Drug	Teneligliptin 10 mg
Teneligliptin 20 mgAlso: MP-513	Drug	Teneligliptin 20 mg
Teneligliptin 40 mgAlso: MP-513	Drug	Teneligliptin 40 mg
Placebo	Drug	Placebo

Primary outcome

Change From Baseline in HbA1c at Week 12
Time frame: 12 weeks
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.

3 secondary outcomes

Change From Baseline in Fasting Plasma Glucose at Week 12
Time frame: 12 weeks
Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12
Time frame: 12 weeks
Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12
Time frame: 12 weeks

Results and safety

Results posted to the registry on 31 May 2013, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Placebo	80	77
Teneligliptin 10 mg	84	83
Teneligliptin 20 mg	79	76
Teneligliptin 40 mg	81	76

Primary outcome: Change From Baseline in HbA1c at Week 12

Time frame: 12 weeks. Least squares mean (Standard Error). Unit: Percent

Measure	Placebo n = 80	Teneligliptin 10 mg n = 84	Teneligliptin 20 mg n = 79	Teneligliptin 40 mg n = 81
Value	0.11 (0.05)	-0.77 (0.05)	-0.80 (0.05)	-0.91 (0.05)

Population analysed: The full analysis set, consisting of all type 2 diabetic patients, who received at least one dose of study drug and who had at least one efficacy data after randomization. Analysis based on last observation carried forward, where the last postbaseline double-blind observed value was carried forward and used for Week 12 where data was missing.

3 secondary outcomes are reported in the full results.

Adverse events

Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo	1 of 80 (1.3%)	44 of 80 (55%)	Not reported
Teneligliptin 10 mg	0 of 84 (0%)	50 of 84 (59.5%)	Not reported
Teneligliptin 20 mg	0 of 79 (0%)	40 of 79 (50.6%)	Not reported
Teneligliptin 40 mg	0 of 81 (0%)	46 of 81 (56.8%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Type 2 Diabetes

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Takashi Kadowaki, Professor, MD,PhD study director

Tokyo University

Kazuoki Kondo, MD study director

Tanabe Pharma Corporation

Tadashi Yoshida, MD study director

Tanabe Pharma Corporation

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Teneligliptin 10mg, Teneligliptin 20 mg and Teneligliptin 40 mg in people with Type 2 Diabetes, run by Tanabe Pharma Corporation at 1 site in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 May 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in HbA1c at Week 12 (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00628212.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.